"In the second quarter of 2014, we continued to achieve product development and financial milestones as we advance our best-in-class cell therapy platform which leverages the unique properties of the hair follicle to treat cellular deficits," said
-- Shiseido opens purpose built facility to advance their planned clinical trials for the treatment of pattern baldness based on RepliCel's licensed cell therapy technology -- Completed pre-clinical filing regulatory meetings with
Health Canadafor Phase 1/2 chronic Achilles tendinosis program -- Completed pre-clinical regulatory meetings with German authorities for Phase 1 aging and sun damaged skin program -- Exercise of 1,508,512 warrants yielding $834,218-- Completed private placement totaling $3.99 million, providing capital to execute on expanding clinical initiatives
Expected and planned upcoming milestones and events include:
-- Initiation of a Phase 1/2 Canadian clinical trial for Achilles tendinosis expected in Q4 2014 -- Initiation of a Phase 1 clinical trial in
Germanyfor aging and damaged skin expected in Q4 2014 -- Initiation of a Phase 2 clinical trial in Germanyfor pattern baldness expected in Q4 2014 -- Shiseido, the 4th largest cosmetics company in the world, and our Asian partner, initiating a Phase 2 clinical trial for pattern baldness in Japanexpected in Q4 2014 -- Additional contract opportunities (government, pharmaceutical companies)
The total comprehensive loss for the three and six-month periods ended
Cash and cash equivalents was approximately
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function such as chronic tendinosis, damaged skin and pattern baldness. The company's RCT-01 and RCS-01 cell therapies are designed to treat chronic tendinosis and damaged or aging skin respectively, using fibroblasts isolated from the sheath of the hair follicle. Another of the company's pipeline products, RCH-01 for the treatment of pattern baldness, is manufactured from cells derived from the hair follicle dermal cup. Shiseido Company, Limited has an exclusive geographic license for RCH-01 in certain Asian countries including
This press release contains forward-looking information that involve various risks and uncertainties regarding future events, including statements regarding Shiseido's progress points to both companies advancing Phase 2 pattern baldness clinical activities in the near future, the private placement further validates our approach and our technology, expected and planned upcoming milestones and events, and the timing of trials. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of RepliCel. There are numerous risks and uncertainties that could cause actual results and RepliCel's plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company's clinical trials; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, RepliCel does not intend to update these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
REPLICEL LIFE SCIENCES INC. David Hall, CEO firstname.lastname@example.org Tammey George, Director of Communications 604-248-8696 email@example.com Christina Cameron, Investor Relations firstname.lastname@example.org Source: RepliCel Life Sciences Inc.